Frank D'alessandro, MD
Endocrinology, Diabetes & Metabolism · North Providence, RINPI 1447317730
Payments from drug & device makers
Across 917 payments — averaging $210.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$63K
- Sanofi-aventis U.S. LLC$45K
- Lilly USA, LLC$40K
- Xeris Pharmaceuticals, Inc.$17K
- Johnson & Johnson$10K
- AstraZeneca$7K
- plus $10K from 33 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 182 | $63,123 |
| Sanofi-aventis U.S. LLC | 118 | $45,027 |
| Lilly USA, LLC | 105 | $40,243 |
| Xeris Pharmaceuticals, Inc. | 28 | $17,378 |
| Johnson & Johnson | 38 | $9,995 |
| AstraZeneca(2 entities) | 20 | $7,004 |
| Mannkind Corporation | 59 | $3,937 |
| Novo Nordisk | 128 | $1,791 |
| Abbott | 46 | $690 |
| Cequr Corporation | 3 | $526 |
| Bayer | 17 | $462 |
| Antares Pharma, Inc. | 18 | $410 |
| Tolmar, Inc. | 20 | $344 |
| AbbVie | 15 | $309 |
| Dexcom, Inc. | 17 | $301 |
| Amneal Pharmaceuticals LLC | 34 | $284 |
| Medtronic(2 entities) | 6 | $212 |
| Corcept Therapeutics | 4 | $182 |
| Merck | 20 | $156 |
| Insulet Corporation | 1 | $141 |
| Lexicon Pharmaceuticals, Inc. | 5 | $102 |
| GSK | 5 | $89 |
| Lundbeck LLC | 3 | $63 |
| Esperion Therapeutics, Inc. | 4 | $52 |
| Ascendis Pharma Endocrinology Inc | 2 | $50 |
| Actelion Pharmaceuticals US, Inc. | 2 | $49 |
| Amgen | 2 | $46 |
| Shire North American Group Inc | 2 | $45 |
| Pfizer | 2 | $33 |
| Aytu Biopharma, Inc. | 2 | $30 |
| Eisai Inc. | 1 | $21 |
| Halozyme Inc | 1 | $19 |
| Highridge Medical LLC | 1 | $18 |
| EBI, LLC | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Valeritas, Inc. | 1 | $13 |
How this compares
$193,229 in reported general payments places this provider in the 90th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
See all endocrinology, diabetes & metabolism providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in North Providence
- Frank DalessandroNorth Providence$389
- Sudhir BansalWarwick$2.4M
- Robert DobrzynskiProvidence$245K
- Ricardo Correa MarquezEast Providence$94K
- Robert SmithProvidence$80K
- Joseph TucciProvidence$30K
- Amanda FernandesRiverside$28K
- Judith GilmoreWakefield$11K
- Stephanie CurryJohnston$8K
- Beatriz DemoranvilleWarwick$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.